Emerging targets for therapy in ALD: Lessons from NASH

Area of Science:

• Hepatology
• Metabolic Syndrome
• Liver Disease Pathogenesis

Background:

• Alcohol-associated liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are leading causes of liver disease globally.
• Both ALD and NAFLD are linked to metabolic dysfunction and currently lack effective targeted therapies.
• Current management focuses on risk factor control, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review and compare the conserved and distinct pathogenic pathways in ALD and NAFLD.
• To identify potential shared and unique therapeutic targets for these liver diseases.
• To explore the application of NAFLD metabolic targets to ALD.

Main Methods:

• Literature review focusing on conserved and distinct pathogenic pathways in ALD and NAFLD.
• Analysis of metabolic derangements and their role in disease progression.
• Identification of therapeutic targets based on shared and unique molecular mechanisms.

Main Results:

• ALD and NAFLD share conserved pathways including lipid metabolism, apoptosis, innate immunity, and stellate cell activation.
• Distinct pathways in ALD and NAFLD include gut microbiome alterations, glucose metabolism/insulin resistance, inflammatory signaling, and microRNA dysregulation.
• Histological features like steatosis, inflammation, fibrosis, and cirrhosis are common to both diseases.

Conclusions:

• Shared pathogenic pathways offer potential for dual-targeting therapies for ALD and NAFLD.
• Distinct pathways present opportunities for disease-specific therapeutic interventions.
• Further research into these metabolic targets is crucial for developing effective treatments for common liver diseases.